This manuscript compares the efficacy and safety of duloxetine with placebo in Taiwanese women with SUI. Materials and Methods: Taiwanese women with SUI were were randomly assigned to placebo (n = 61) or duloxetine 80 mg/day (n = 60) in this double-blind, 8-week, placebo-controlled study. Outcome variables included: incontinence episode frequency (IEF), Incontinence Quality of Life questionnaire (I-QOL) scores, and Patient Global Impression of Improvement rating (PGI-I).

Decrease in IEF was significantly greater in duloxetine-treated than placebo-treated women (69.98% vs 42.56%, P < .001). No treatment differences in I-QOL scores were significant. There were siginificant differences in PGI-I rating. Treatment-emergent adverse events (TEAEs) were experienced by more duloxetine-treated than placebo-treated women (80.0% vs 44.3%; P < .001). Discontinuations due to adverse events were significantly greater for duloxetine-treated than placebo-treated women (26.7% vs 6.6%; P = .003).

Data provide evidence for the safety and efficacy of duloxetine for the treatment for Taiwanese women with SUI.

Written by
Lin AT, Sun MJ, Tai HL, Chuang YC, Huang ST, Wang N, Zhao YD, Beyrer J, Wulster-Radcliffe M, Levine L, Chang C, Viktrup L.

Reference
BMC Urol. 2008 Jan 25;8(1):2.
doi:10.1186/1471-2490-8-2

PubMed Abstract
PMID:18221532

UroToday.com Stress Urinary Incontinence Section

UroToday.com Female Urology Section

Please log-in or register in order to submit comments.

Powered by AkoComment!